Literature DB >> 17904955

The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.

Bradley J Monk, Thomas J Herzog.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904955     DOI: 10.1016/j.ajog.2007.08.030

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  7 in total

1.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

2.  Disparities in human papillomavirus vaccine completion among vaccine initiators.

Authors:  Betty Chou; Lauren S Krill; Bernice B Horton; Christopher E Barat; Cornelia L Trimble
Journal:  Obstet Gynecol       Date:  2011-07       Impact factor: 7.661

3.  Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer.

Authors:  Özlem Ercelep; Deniz Tataroğlu; Melike Özçelik; Heves Sürmeli; Mustafa Değirmenci; Mevlüde İnanç; Mehmet Aliustaoğlu; Mahmut Gümüş
Journal:  Turk J Obstet Gynecol       Date:  2020-07-29

4.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

5.  EGCG suppresses Fused Toes Homolog protein through p53 in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Zhengzhe An; Jae-Ran Yu; Woo-Yoon Park
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

6.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

7.  Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells.

Authors:  Oana Tudoran; Olga Soritau; Ovidiu Balacescu; Loredana Balacescu; Cornelia Braicu; Meda Rus; Claudia Gherman; Piroska Virag; Florin Irimie; Ioana Berindan-Neagoe
Journal:  J Cell Mol Med       Date:  2012-03       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.